Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome "EXAMINE"

Completed

Phase 3 Results

Summary of Purpose

The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 15 April 2014.

1 Sep 2009 28 Aug 2009 1 Apr 2013 1 Jun 2013 1 Apr 2014 8 Mar 2014
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Parallel Assignment

Contacts